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Background: Employment status at time of first heart failure (HF) hospitalization may be an indicator of 
both self-perceived and objective health status. In this study, we examined the association between 
employment status and the risk of all-cause mortality and recurrent HF hospitalization in a nationwide cohort 
of patients with HF.  
Methods and Results: We identified all patients of working age (18-60 years) with a first HF hospitalisation 
in the period 1997-2015 in Denmark, categorized according to whether or not they were part of the 
workforce at time of the index admission. The primary outcome was death from any cause and the secondary 
outcome was readmission for HF. Cumulative incidence curves, binomial regression and Cox regression 
models were used to assess outcomes. Of 25571 patients with a first hospitalization for HF, 15428 (60%) 
were part of the workforce at baseline. Patients in the workforce were significantly younger (53 vs. 55 years) 
more likely to be male (75% vs 64%) and less likely to have diabetes (13% vs 22%) and chronic obstructive 
pulmonary disease (5% vs 10%), all p-values <0.001. Not being part of the workforce was associated with a 
significantly higher risk of death (HR: 1.59 [95% CI 1.50–1.68]) and rehospitalisation for HF (HR: 1.09 
[95% CI 1.05–1.14]), in analyses adjusted for age, sex, comorbidities, education level, calendar time, 
duration of first HF hospitalization.  
Conclusion: Not being part of the workforce at time of first HF hospitalization was independently associated 
with increased mortality and recurrent HF hospitalization. 








Heart failure (HF) is a common and costly disease associated with high risk of hospitalization and death.1-4 
Despite advances in treatment, HF is still associated with a reduced quality of life, and a prognosis 
comparable with some types of cancer.5  The ability to work provides valuable information on patients’ well-
being and performance status. It might also have an impact on subsequent disease trajectory as employment 
status might be associated with better uptake of cardiac rehabilitation and adherence to evidence-based 
therapy. Contrarily, detachment from the workforce has been associated with increased risk of depression, 
mental health problems and even suicide.6-8 Several parameters have been identified as independent 
predictors of morbidity and mortality in HF, including age, sex, ejection fraction, diabetes, renal function and 
New York Heart Association functional class (NYHA).9, 10  Employment status could be a relevant additional 
predictive factor in younger patients with HF, but its importance for prognosis is unclear.11-14 We 
hypothesized that employment status is correlated with prognosis in terms of morbidity and mortality for 
patients with HF. Information about the relationship between employment status and morbidity and mortality 
could help risk-stratify younger HF patients and identify individuals who might benefit from more intensive 
rehabilitation. Therefore, we examined the association between employment status and the risk of death from 











Nationwide administrative registries were linked by use of unique personal identification numbers assigned 
to all Danish residents.15 We were able to collect information on hospitalizations, prescribed medications, 
education level, public welfare payments, and vital status on an individual level.16, 17 
Study population and baseline variables 
Patients aged 18-60 years at time of first HF hospitalization in the period 1997-2015 were included in the 
study (Appendix 1). Employment status was determined during the 5 weeks prior to first hospitalization for 
HF. Patients who received public support due to reduced working capability in 3 or more of the 5 evaluated 
weeks were classified as detached from the workforce, as done previously.18 Thus patients in the workforce 
also included patients who were unemployed. The evaluation period of 5 weeks was chosen so as not to 
include patients on short-term sick leave and misclassify them as detached from the workforce.                               
The following comorbidities were identified by discharge diagnoses during a 10 year period before first 
hospitalization with HF: ischemic heart disease, cancer, atrial fibrillation, chronic kidney disease, chronic 
obstructive pulmonary disease (COPD), diabetes mellitus, hypertension and stroke. Filled prescriptions for 
glucose lowering drugs 6 months prior to first HF hospitalization were used to identify additional patients 
with diabetes. Procedures for implantation of cardiac devices were identified and prior surgical procedures in 
the form of valve surgery and coronary artery bypass grafting were classified according to NOMESCO 
Classification of Surgical procedures.19 Diagnose and procedure codes are listed in Appendix I.  Baseline use 
of pharmacotherapy was defined by one or more filled in prescriptions 6 months prior to first HF 
hospitalization. Use of the following drugs was assessed: angiotensin-converting enzyme inhibitors (ACE-I) 
or angiotensin-II receptor blockers (ARB), aspirin, calcium channel blockers, digoxin, clopidogrel, 
mineralocorticoid receptor antagonists (MRAs), statins, β blockers, loop-diuretics, antidepressants and 
antipsychotics. We did not account for treatment initiated during the index hospitalization for HF. Income 
  
was calculated as 5-year average family income prior to first HF hospitalization and further classified into 
quartiles.  
Outcome measures 
Our primary outcome was death from any cause. Recurrent hospitalization for HF was evaluated as the 
secondary outcome. Patients were followed from first hospitalization for HF until date of emigration, death, 
December 31, 2015 or a maximum of 5 years.  
In a sensitivity analysis we further categorized patients not in the workforce at baseline according to whether 
their employment status 1 year before first HF hospitalization and examined the association with mortality 
and recurrent HF hospitalization.  We also tentatively adjusted for prior outpatient clinic visit for heart 
failure. Furthermore we repeated our cox regression analyses on death including HF medication and cardiac 
devices. 
Statistics 
Differences in baseline characteristics among patients in and out of the workforce were tested by use of 
Wilcoxon’s test for continuous variables and χ2-test for categorical variables. Cumulative incidence curves 
were estimated for death and rehospitalization for HF, respectively. In analyses of rehospitalization, death 
was treated as a competing risk. Cumulative incidence curves were estimated by use of the Aalen-Johansen 
method.20 Unadjusted differences were evaluated by use of Gray’s test. Hazard ratios (HRs) for death and 
rehospitalization were calculated by use of cause specific Cox regression models. Cox regression analyses 
were adjusted for age, sex, level of education, calendar time, length of first HF hospitalization, 
antidepressants, antipsychotics and comorbidities i.e. ischemic heart disease, atrial fibrillation, chronic 
kidney disease, COPD, diabetes, hypertension, stroke and cancer. All factors were included in each of the 
presented adjusted models.  Log (-log(survival)) curves was used to evaluate the proportional hazard 
assumption. Interactions between age, sex, comorbidities and employment status were tested for both 
outcomes and none were found to be significant. The rate of total hospitalizations for HF was compared by 
use of negative binomial regression with logarithm of the duration of follow-up as the offset.21  Data 
  
management and statistical analyses were performed by use of SAS statistical software package, version 9.4 
(SAS Institute, Cary, NC, USA) and R, version 3.3.2 (R development Core Team). 
Results 
Baseline characteristics of the study population 
We identified 25571 patients with a first hospitalization for HF in the period 1997-2015. Of these, 15428 
individuals (60%) were part of the workforce at baseline. Patients in the workforce were significantly 
younger (median age 53 years vs 55 years), more were men (75% vs 65%) and they had a higher level of 
education (higher education: 17% vs 10%); Table 1. All comorbidities were less prevalent among patients in 
the workforce group. Patients in the workforce were more often treated with β-blockers (56% vs 51%) and 
ACE-I/ARB (66% vs 63%) but were less likely to be on loop diuretics (49% vs 61%) and MRAs (21% vs 
26%). 
Mortality 
The median follow-up of was 781 days; Q1-Q3 105-1825 days. During this period, 2205 (14%) died in the 
workforce group and 3213 (32%) in the non-workforce group (risk of death 14% [13%-16%] vs. 32% [31%-
33%]; P<0.0001; Figure 1). The unadjusted HR for all-cause mortality was 2.15 (95% CI 2.03-2.27) for 
patients out of the workforce compared to patients in the workforce. In adjusted analyses, HF patients not 
part of the workforce at baseline remained at higher risk of death (HR 1.59 [1.50–1.68]; P<0.0001; figure 2). 
This risk was comparable to that of having diabetes (HR 1.41 [1.33-1.51]) and stroke (HR 1.36 [1.22-1.50]). 
Other factors associated with higher risk of death included older age, male sex, lower level of education, use 
of antidepressants and antipsychotics and all comorbidities; Figure 2. 
In a sensitivity analysis, patients who were not in the workforce at baseline nor at 1 year before 
hospitalization (n=7718) had a mortality risk of HR 1.66 [1.56-1.77], compared to those in the workforce at 
baseline. Patients with recent detachment from the workforce (<1 year) had a mortality risk of HR 1.38 
[1.25-1.51] compared patients in the workforce at baseline. There was a significant interaction between 
  
length of detachment (≥1year vs. <1year) and employment status in relation to mortality (P<0.0001). 3637 
(14%) of the patients were seen in an outpatient clinic prior to first HF hospitalization adding this 
information to the main analyses did not change the results. In a cox regression analysis including 
cardiovascular medications and cardiac devices we found that HF patients not part of the workforce at 
baseline still had a higher risk of death. ARB, β blockers and Implantable cardiac defibrillators were 
associated with lower likelihood of death. Conversely, loop-diuretics and MRAs were associated with higher 
likelihood of Death (Supplementary figure 1). 
 
Rehospitalization for heart failure 
During follow-up, 6495 (42%) in the workforce group and 4739 (47%) in the non-workforce group were 
rehospitalized for HF (5-year risk of rehospitalization for HF 45% [44%-46%] vs. 47% [46%-48%]; P=0.03; 
figure 3). In Cox-regression analyses this yielded an unadjusted HR of 1.09 [1.05-1.13; P=0.0005] and an 
adjusted HR of 1.09 [1.05-1.14; P<0.0001]. Other factors associated with rehospitalization for HF included 
younger age, male sex, use of antidepressants, COPD, diabetes and cancer; Figure 4. In adjusted analyses the 
risk of rehospitalization for HF during the first year after discharge from first HF hospitalization was HR 
1.05 [1.01-1.10; P=0.04]. Whereas the risk of rehospitalization was HR 1.20 [1.11-1.29; P<0.0001] from 1 to 
5 years after first hospitalization for HF. The crude incidence rate of total HF hospitalizations was 354 
hospitalizations per 1000 person years for patients out of the workforce and 302 hospitalizations per 1000 




The present study examined the association between employment status and the risk of death and recurrent 
HF hospitalization in a nationwide cohort of 25571 HF patients. The main result of the study was that HF 
  
patients not in the workforce had a significant higher adjusted risk of death, and recurrent hospitalization for 
HF, although not as pronounced.  This excess risk of death in patients not in the workforce was comparable 
to that associated with comorbidities such as diabetes or prior stroke.   
Several prognostic factors for patients with HF have been identified and included in risk scores.9, 10, 22-24  
However, none of these models have included variables assessing functional performance in the community 
such as employment status.  Evidently, employment status is only relevant in HF patients of working age, but 
in this subgroup of patients, it may be valuable when quantifying the overall prognosis of young HF patients. 
The exact mechanism of how employment status is related to mortality and recurrent HF hospitalization is 
complex and most likely multi-factorial. The ability to work can be seen as a measure of good performance 
status and may reflect that patients are able to meet the physical requirements of a full-time job. As 
performance status is closely associated with morbidity and mortality in HF this could, at least in part, 
explain the association we found. However, employment status is more than just another physical 
measurement as it also influences patients’ quality of life and has been shown to be important for mental 
health and well-being.6, 8 Quality of life is also associated with outcome in heart failure. There may be other 
more indirect mechanisms through which employment status influences outcome. For example, loss of 
income could lead to poorer nutrition and, through loss of self-esteem, adoption of unhealthy habits such as 
excessive alcohol consumption or resumption of smoking. Similarly, hopelessness or despair might reduce 
adherence to medical therapy and a healthy lifestyle.  Thus both from a physical and psychological 
perspective, it makes sense to include employment status as part of the evaluation of young patients with HF. 
While it may not be surprising that employment status is related to prognosis, the strength of the association 
is. Employment status was associated with a risk of death comparable to that of comorbidities such as 
diabetes and stroke.9, 25  For different reasons patients out of the workforce are not able to be part of the 
workforce. These reasons are likely to be associated with higher likelihood of death. We illustrate and adjust 
our analyses for some of the reasons i.e. higher age, male gender, lower level of education, length of first HF 
hospitalization, use of antidepressants and antipsychotics and history comorbidities in the form of chronic 
kidney disease, COPD, diabetes, stroke and cancer. But after adjusting for these factors, known to be 
  
associated with worse prognosis, the association of employment status and death is still highly significant. It 
is highly likely that not being part of the workforce captures some otherwise unmeasured covariates that 
influence prognosis in this population. Socio-economic characteristics have been shown to be related to the 
use of evidence based medication and cardiac devices. 26 Thus employment status might also have impact on 
use of medication and cardiac devices which in return could mediate some of the effect on mortality and 
rehospitalization related to employment status. Thus, further knowledge on which elements workforce 
exclusion covers could be valuable and might be target for intervention.27 Thus so far employment status is 
an interesting and valuable factor to assess. 
The main strength of this study is the use of nationwide registries with complete unselected information on 
all patients admitted to a hospital with HF as a discharge diagnosis. These registries made it possible for us 
to link weekly updated data on occupational status with data on hospitalization, pharmacotherapy use and 
vital status on a nationwide scale. We chose to look at workforce availability instead of employment and thus 
our results should not be affected by any fluctuations in the employment opportunities. The main limitation 
of the study is missing information on clinically important variables especially ejection fraction and NYHA 
status. It is highly likely that not being part of the workforce captures some otherwise unmeasured covariates 
that influence prognosis in this population and caution should be used when interpreting the finding that 
employment status is an independent  predictor of mortality and rehospitalization among HF patients. The 
observational nature of the study means that the effect of unmeasured confounders cannot be excluded and 
that our findings reflect associations and not causal connections.  
Workforce detachment at time of first HF hospitalization was associated with a higher subsequent risk of 
death and rehospitalization for HF. Patients outside the workforce had a risk of death comparable to that of 
patients with diabetes or stroke. Employment status could be a valuable factor in the evaluation of young HF 
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Table and figure legends 
Table 1 Baseline characteristics according to employment status at time of first HF 
hospitalization. 
Figure 1 Risk of death among patients in and out of the workforce at time of first HF 
hospitalization (n= 25571). 
Figure 2 Results from one multivariable Cox regression model of factors associated with 
death among patients in and out of the workforce at time of first HF 
hospitalization (n=25571). 
Figure 3 Risk of rehospitalization for HF with death as competing risk (i.e. death before 
HF rehospitalization) among patients in and out of the workforce (n=25571). 
Figure 4 Results from one multivariable cause specific Cox regression model of factors 
associated with rehospitalization for HF among patients in and out of the 
workforce (n=25571). 
Supplementary figure 1 Results from one multivariable Cox regression model of factors including HF 
medication and cardiac devices associated with death among patients in and out 
of the workforce at time of first HF hospitalization (n=25571). 
 







Employment status In the workforce Out of the workforce 
No. Patients 15428 10143 
Age, median (IQR) 53 (47-57) 55 (50-58) 
Male 11584 (75%) 6519 (64%) 
Highest education Level   
Basic school <10 yrs 5095 (33%) 5055 (50%) 
High school, +3yrs  647 (4%)  262 (3%) 
Vocational Education 6062 (39%) 3411 (34%) 
Short/medium higher, +2-4 yrs 2058 (13%) 858 (8%)  
Long higher, +≥5 yrs  677 (4%) 157 (2%)  
Unknown 889 (6%) 400 (4%)  
Income group #   
Q1 (lowest) 3271 (21%) 3121 (31%) 
Q4 (highest) 4939 (32%) 1454 (14%) 
Length of first HF hospitalization   
0-2 days 5404 (35%) 3692 (36%) 
3-7 days 5718 (37%) 3346 (33%) 
> 7 days     4306 (28%) 3105 (31%) 
Comorbidity (%)   
Ischemic heart disease 2993 (19%) 2379 (23%) 
Atrial fibrillation 1459 (9%) 950 (9%) 
Cancer 487 (3%) 643 (6%) 
COPD 732 (5%) 998 (10%) 
  
Diabetes 1950 (13%) 2267 (22%) 
Hypertension 2584 (17%) 2061 (20%) 
Chronic kidney disease 422 (3%) 584 (6%) 
Stroke 439 (3%) 696 (7%) 
Surgical procedures   
Valve surgery 287 (2%) 254 (3%) 
CABG 471 (3%) 610 (6%) 
Pharmacotherapy* (%)   
Loop diuretics 7598 (49%) 6192 (61%) 
Antiplatelets, any 6002 (39%) 4559 (45%) 
β-blockers 8702 (56%) 5223 (51%) 
ACE-I/ARB 10188 (66%) 6372 (63%) 
Statins 4827 (31%) 3711 (37%) 
Thiazides 1783 (12%) 1581 (16%) 
Ca2+ channel blockers 2342 (15%) 2240 (22%) 
Digoxin 2646 (17%) 1636 (16%) 
MRAs 3182 (21%) 2598 (26%) 
Antidepressants 1410 (9%) 2287 (23%) 
Antipsychotics 436 (3%) 1199 (12%) 
CABG- coronary artery bypass grafting; COPD - chronic obstructive pulmonary disease;  
MRAs - mineralocorticoid receptor antagonists; 
ACE-I angiotensin-converting enzyme inhibitors, ARB- angiotensin-II receptor blockers;  
*Filled in prescriptions 180 days prior to admission; 



































Appendix 1  
Heart failure I11.0, I13.0, I13.2, I42, I50 
Renal disease N03, N04, N17-N19, R34, I12, I13  
Hypertension I10-I15  
Stroke I60-I61, I63-I64 
Diabetes mellitus E10-E14  
Ischemic heart disease I20-I25  
Atrial fibrillation I48 
Myocardial infarction I21, I22 
Cancer C00-C99 
COPD J42, J44 
  
CABG KFNA-E 
Valve surgery KFG, KFK, KFM, KFJE-F 
 
 
 
 
 
 
